News 14.10.2024 SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of...
News 11.10.2024 Securecell is introducing a series of innovative high-throughput solutions to transform the way bioprocess development is done. These solutions are designed to address inefficiencies in traditional workflows by providing a high degree of automation and integration. The centerpiece of Securecell’s innovation is the Integra1 64 2, a fully automated end-to-end bioprocess development...
News 10.10.2024 Somagenetix AG, a pioneering biotech company dedicated to revolutionizing gene therapy for phagocyte disorders, announced today the initial closing of its Series A financing round, raising CHF 10 million. The round was led by Vi Partners, renowned venture capital firm specialized in life sciences and technology investments. Among others, existing...
News 10.10.2024 Boston, MA and Switzerland, 10 October 2024 – CUTISS AG, a life sciences company at the forefront of tissue engineering therapy and regenerative medicine, announced the first ever grafting of denovoSkin™, its autologous, bio-engineered dermo-epidermal skin graft, in a compassionate reconstructive procedure, with the patient also being the first ever U.S....
News 10.10.2024 Schlieren (Zurich), Switzerland, October 10, 2024 – Kuros Biosciences (“Kuros”), a leader in advanced bone healing technologies, today announced its financial performance for the first nine months of 2024. Revenue from direct MagnetOs product sales rose 149% in the first nine months of 2024, to CHF 50.6 million from CHF...